Literature DB >> 22783402

Role of an MDM4 polymorphism in the early age of onset of nasopharyngeal carcinoma.

Yao Wei Zhang1, Jian Guan, Yong Zhang, Yu Rong Qiu, Long Hua Chen.   

Abstract

Mouse double minute 4 (MDM4) is a critical negative regulator of the tumor suppressor p53. The results of studies have revealed that an MDM4 polymorphism (rs1563828) may contribute to the earlier onset of several malignant diseases. However, the correlation between this polymorphism and nasopharyngeal carcinoma (NPC) susceptibility has not been explored. We performed a case-control study with 210 NPC patients and 200 healthy controls. Significant associations were found when comparing the age of onset of NPC according to the rs1563828 genotype (P=0.01). The average age of onset of NPC in patients with the TT, CC and CT genotypes was 39.3, 48.2 and 45.5 years, respectively. Homozygous variant (TT) carriers developed NPC at an earlier age than homozygous (CC) carriers, such that the age of onset was accelerated by 8.9 years (P=0.002). Our data suggest that rs1563828 is a modifier of the age of onset of NPC in the population studied. The age of onset for NPC with TT homozygotes was earlier than CC carriers.

Entities:  

Year:  2012        PMID: 22783402      PMCID: PMC3389627          DOI: 10.3892/ol.2012.630

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  18 in total

1.  MDM4 downregulates p53 transcriptional activity and response to stress during differentiation.

Authors:  Sergio Ménendez; Amanda M Goh; Suzanne Camus; Kee Woei Ng; Nelly Kua; Vinay Badal; David P Lane
Journal:  Cell Cycle       Date:  2011-04-01       Impact factor: 4.534

2.  Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck.

Authors:  Hongping Yu; Yu-jing Huang; Zhensheng Liu; Li-E Wang; Guojun Li; Erich M Sturgis; David G Johnson; Qingyi Wei
Journal:  Mol Carcinog       Date:  2011-06-07       Impact factor: 4.784

3.  Polymorphisms of MDM4 and risk of squamous cell carcinoma of the head and neck.

Authors:  Hongping Yu; Li-E Wang; Zhensheng Liu; Sheng Wei; Guojun Li; Erich M Sturgis; Qingyi Wei
Journal:  Pharmacogenet Genomics       Date:  2011-07       Impact factor: 2.089

4.  MDM2 promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population.

Authors:  Gangqiao Zhou; Yun Zhai; Ying Cui; Xiumei Zhang; Xiaojia Dong; Hao Yang; Ying He; Kaitai Yao; Hongxing Zhang; Lianteng Zhi; Xiaoyan Yuan; Wei Qiu; Xiaoai Zhang; Yan Shen; Boqing Qiang; Fuchu He
Journal:  Clin Cancer Res       Date:  2007-05-01       Impact factor: 12.531

5.  MDM4 (MDMX) overexpression enhances stabilization of stress-induced p53 and promotes apoptosis.

Authors:  Francesca Mancini; Francesca Gentiletti; Marco D'Angelo; Simona Giglio; Simona Nanni; Carmen D'Angelo; Antonella Farsetti; Gennaro Citro; Ada Sacchi; Alfredo Pontecorvi; Fabiola Moretti
Journal:  J Biol Chem       Date:  2003-12-01       Impact factor: 5.157

6.  Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations.

Authors:  Shenying Fang; Ralf Krahe; Guillermina Lozano; Younghun Han; Wei Chen; Sean M Post; Baili Zhang; Charmaine D Wilson; Linda L Bachinski; Louise C Strong; Christopher I Amos
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

7.  Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene.

Authors:  Gurinder Singh Atwal; Tomas Kirchhoff; Elisabeth E Bond; Marco Montagna; Marco Monagna; Chiara Menin; Roberta Bertorelle; Maria Chiara Scaini; Frank Bartel; Anja Böhnke; Christina Pempe; Elise Gradhand; Steffen Hauptmann; Kenneth Offit; Arnold J Levine; Gareth L Bond
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-04       Impact factor: 11.205

Review 8.  MDM2 and MDM4: p53 regulators as targets in anticancer therapy.

Authors:  Franck Toledo; Geoffrey M Wahl
Journal:  Int J Biochem Cell Biol       Date:  2007-04-08       Impact factor: 5.085

9.  Combined effects of MDM2 SNP 309 and p53 mutation on oral squamous cell carcinomas associated with areca quid chewing.

Authors:  Shiang-Fu Huang; I-How Chen; Chun-Ta Liao; Hung-Ming Wang; Saou-Hsing Liou; Ling-Ling Hsieh
Journal:  Oral Oncol       Date:  2008-05-19       Impact factor: 5.337

10.  Identification of genes with allelic imbalance on 6p associated with nasopharyngeal carcinoma in southern Chinese.

Authors:  Yan Li; Li Fu; Alissa Michelle Go Wong; Yan-Hui Fan; Miao-Xin Li; Jin-Xin Bei; Wei-Hua Jia; Yi-Xin Zeng; Danny Chan; Kenneth M C Cheung; Pak Sham; Daniel Chua; Xin-Yuan Guan; You-Qiang Song
Journal:  PLoS One       Date:  2011-01-20       Impact factor: 3.240

View more
  5 in total

1.  A PRISMA-compliant meta-analysis of MDM4 genetic variants and cancer susceptibility.

Authors:  Yajing Zhai; Zhijun Dai; Hairong He; Fan Gao; Lihong Yang; Yalin Dong; Jun Lu
Journal:  Oncotarget       Date:  2016-11-08

2.  The associations between MDM4 gene polymorphisms and cancer risk.

Authors:  Ming-Jie Wang; Yong-Jun Luo; Zhi-Yong Shi; Xiao-Liang Xu; Guo-Liang Yao; Rui-Ping Liu; Hui Zhao
Journal:  Oncotarget       Date:  2016-08-23

3.  A preliminary Study on the Effect of Head and Neck Chemoradiotherapy on Systematic Immunity.

Authors:  Weiqiang Huang; Yao Fan; Xiaoya Cheng; Huazhen Liang; Hua Pan; Ting Xiao; Min Chen; Jian Guan
Journal:  Dose Response       Date:  2019-10-28       Impact factor: 2.658

4.  The Correlation of Mouse Double Minute 4 (MDM4) Polymorphisms (rs4245739, rs1563828, rs11801299, rs10900598, and rs1380576) with Cancer Susceptibility: A Meta-Analysis.

Authors:  Jian Chen; Xudong Li; Ruihao Liu; Yufen Xie; Zhigao Liu; Haiwei Xiong; Yingliang Li
Journal:  Med Sci Monit       Date:  2022-03-29

5.  The Role of hsa-miR-21 and Its Target Genes Involved in Nasopharyngeal Carcinoma.

Authors:  Thuan Duc Lao; Minh Trong Quang; Thuy Ai Huyen Le
Journal:  Asian Pac J Cancer Prev       Date:  2021-12-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.